Introduction
You may have patients seeking treatment for multiple affected areas and/or a non-steroidal alternative.

Consider Staquis® for your patients ≥ 3 months of age and older with mild-to-moderate atopic dermatitis (AD).^1†

As defined in Staquis^® clinical trials:

• Mild, or ISGA Grade 2, presents with faint pink erythema and mild induration/papulation and no oozing/crusting²
• Moderate, or ISGA Grade 3, presents with pink-red erythema and moderate induration/papulation with or without oozing/crusting²

^†For topical use only, not for ophthalmic, oral or intravaginal use.¹

References

1. Staquis® (crisaborole) latest approved prescribing information.
2. Paller A, Tom W et al. J Am Acad Dermatol 2016;75(3):494–503.e6.